Blue Star reports a 25% increase in net profit for Q2FY27, with revenue rising 21% to about ₹2,931 crore, driven by stronger operating performance across multiple segments. One outlet also notes a reported exceptional gain during the quarter tied to the sale of the company’s MedTech business. However, rising material costs are cited as a pressure on margins.
Following the results, Blue Star shares fall by around 5% in early trading. NDTV highlights the stock drop alongside UBS’s decision to keep a “Buy” rating and a target price of Rs 2,000, including a stated view of upside. Separately, the Free Press Journal provides additional quarter and half-year figures (including EBITDA growth, order book and cash position) and includes management commentary about expected demand for room air conditioners and data centre MEP projects. Another NDTV item focuses more narrowly on the revenue and profit increases, without additional market or brokerage framing.